Solasia Pharma K.K.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Solasia Pharma K.K.
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.
BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.
Prices for J&J and Pfizer’s COVID-19 vaccines will be watched closely as India permits private sales. While demand is set to spike with age criteria for those eligible to receive the shots expanded, local manufacturers Serum Institute and Bharat Biotech are ramping up capacities with the government’s help.
Based in Cambridge UK, Dunad believes it has developed a platform which is "tuneable and highly selective" and represents a new and differentiated targeted protein degradation approach.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- JapanBridge K.K.
- Solasia Medical Information Consulting (Shanghai) Co. Ltd.